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Introduction and context {#s01}
========================

Autoimmune channelopathies are becoming one of the exciting areas of neurological diseases in clinical practice because, though relatively uncommon (collectively perhaps 20 per million per year), diagnosis of these conditions usually indicates a significant clinical improvement following immunotherapies that reduce autoantibody levels. The field stems from three decades of research into myasthenia gravis and the Lambert-Eaton myasthenic syndrome \[[@bib-001],[@bib-002]\]; in these conditions, autoantibodies to muscle nicotinic acetylcholine receptors (AChRs) or voltage-gated calcium channels (P/Q-type), respectively, are the main pathogenic agents and cause destruction and/or downregulation of their targets, leading to neuromuscular junction transmission failure ([Table 1](#tbl-001){ref-type="table"}) which can be demonstrated in animal models. Newer disorders of peripheral neurotransmission include (a) peripheral nerve hyperexcitability syndromes with antibodies binding to ^125^I-dendrotoxin-labelled *shaker*-type (Kv1) voltage-gated potassium channels (VGKCs) extracted from mammalian cortex \[[@bib-003]\] and (b) autonomic neuropathies with antibodies to ^125^I-epibatidine-labelled ganglionic nicotinic AChRs \[[@bib-004]\].

###### Peripheral nervous system autoimmune channelopathies
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                                          Myasthenia gravis                                                                            Lambert-Eaton myasthenic syndrome                                       Peripheral nerve hyperexcitability syndromes                                         Autonomic neuropathy
  --------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------
  Typical symptoms                        Muscle weakness and fatigue                                                                  Muscle weakness                                                         Muscle twitching, cramps, sweating                                                   Hypotension, constipation, papillary abnormalities, sicca syndrome (dry eyes and mouth)
  Target                                  Muscle nicotinic AChR                                                                        VGCC P/Q-type                                                           Dendrotoxin-binding VGKC Kv1.1, 1.2, 1.6 complexes extracted from mammalian cortex   Ganglionic nicotinic AChR (alpha 3)
  Tumour association or other pathology   Thymoma, thymic hyperplasia or idiopathic                                                    Small-cell lung cancer common in adults (about 50%)                     Thymoma, small-cell lung cancer in about 20%                                         Small-cell lung cancer or other tumours uncommon
  Main pathogenic mechanism               Complement-mediated damage, increased AChR degradation, some direct block of AChR function   Increased VGCC degradation, no evidence of complement-mediated damage   Probably increased VGKC degradation with no apparent complement-mediated damage      Direct block of function and increased degradation
  Disease course                          Usually chronic, rare spontaneous remissions                                                 Usually chronic, may improve with tumour removal                        Can be chronic or monophasic, postinfectious or postallergic                         Monophasic or chronic, postinfectious

AChR, acetylcholine receptor; VGCC, voltage-gated calcium channel; VGKC, voltage-gated potassium channel.

Over the last decade or so, a new family of antibody-associated diseases has emerged that is beginning to overturn previous concepts that regarded the brain as immune-privileged and protected by an impermeable blood-brain barrier. First, glutamate receptor (GluR3) antibodies were present in children with the very rare but devastating form of epilepsy called Rasmussen encephalitis \[[@bib-005]\], but these findings were not always confirmed in other cohorts of patients \[[@bib-006]\], and the main pathology is now thought to be cellular rather than antibody-driven \[[@bib-007]\]. The paradigm shift really began with the finding of very high VGKC antibody levels in patients with limbic encephalitis - which includes seizures, psychological disturbance, memory loss and high signal on magnetic resonance imaging (MRI) in the medial temporal lobes - who responded convincingly to immunotherapies such as plasma exchange (which removes circulating plasma components such as antibodies and replaces them with substitute plasma proteins; see [Figure 1](#fig-001){ref-type="fig"}) \[[@bib-008]-[@bib-010]\]. Until then, limbic encephalitis was almost always recognised as 'paraneoplastic' (that is, associated with a T cell-mediated immune response to a tumour \[[@bib-011]\]) and with a poor response to treatments. The VGKC antibody-associated central nervous system (CNS) phenotypes are now recognised widely, are usually nonparaneoplastic and include patients with some form of epilepsy \[[@bib-012],[@bib-013]\] or Morvan syndrome \[[@bib-014]\]. However, despite colocalisation with antibodies to different Kv1 subtypes on brain tissue and in transfected HeLa cells expressing different Kv1 subtypes, the specificity of the antibodies is not altogether clear \[[@bib-015]\]; a new finding is that many of the antibodies bind not to the Kv1s themselves but to other juxtaparanodal proteins, such as contactin-associated protein 2 (Caspr2), that form part of the VGKC complex after extraction from brain tissue. Antibodies to Caspr2 are particularly frequent in patients with Morvan syndrome (S Irani, S Alexander, A Vincent, unpublished data).

![Aspects of the new autoimmune channelopathies](1757-594X-0001-0000000061-g001){#fig-001}

Major recent advances {#s02}
=====================

Some patients presenting with symptoms of cognitive problems, psychiatric disturbance or epilepsy were found to have antibodies that bound to the proximal dendrites of the hippocampal neuropil \[[@bib-016]\], distinct from the binding of VGKC antibodies more distally \[[@bib-008],[@bib-016]\]; many of these antibodies were subsequently shown to be directed against *N*-methyl-[d]{.smallcaps}-aspartate receptors (NMDARs) (NR1/NR2B) \[[@bib-017]\], with NR1 as the main target \[[@bib-018]\]. Most of these patients progressed to a more complex phenotype with movement disorders or catatonia, mutism, sleep disturbance and autonomic dysfunction \[[@bib-017],[@bib-018]\]. At first, the syndrome was associated with ovarian teratomas in young women, but in these cases, unlike the traditional paraneoplastic disorders \[[@bib-011]\], the conditions improved when the tumour was removed and immunotherapies given \[[@bib-017]\]. Now many nonparaneoplastic cases are being identified and the phenotype is widening to include both male and female adults, teenagers, and even young children \[[@bib-018],[@bib-019]\] (S Irani, A Vincent, unpublished data). These NMDAR antibodies may be different from those measured by binding to linear peptide sequences of NR2A/NR2B seen in neuropsychiatric patients \[[@bib-020]\] and have the potential to be pathogenic since they target extracellular domains on NR1/NR2B transfected human embryonic kidney cells and substantially reduce the expression of these subunits in primary cultures of hippocampal neurons \[[@bib-018]\]. The NMDAR antibodies were most easily detected in the cerebrospinal fluid (CSF) (at 1:10) compared with serum (at 1:400), and there is substantial intrathecal synthesis of the specific antibody \[[@bib-018]\] ([Table 2](#tbl-002){ref-type="table"}); nevertheless, in absolute terms, serum levels are higher than CSF levels. Recently, antibodies to AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) GluR1/GluR2 were identified in another form of limbic encephalitis that was mostly cancer-related. These patients also showed treatment responses but tended to relapse \[[@bib-021]\].

###### Central nervous system autoimmune channelopathies
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  Examples                                                     VGKC-Ab-limbic encephalitis                                                                   NMDAR-Ab encephalitis                                                                                               AMPAR-Ab encephalitis                                                      Neuromyelitis optica                                                                                                       Glycine receptor antibody-associated disorder
  ------------------------------------------------------------ --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  Typical symptoms                                             Memory loss, seizures, psychiatric or psychological disturbance                               Psychosis, bizarre behaviours, mutism, catatonia, movement disorders, hypothalamic dysfunction                      Memory loss, confusion, seizures, agitation Sometimes downbeat nystagmus   Optic nerve inflammation with visual loss Spinal cord inflammation leading to paralysis, loss of sensation                 Excessive startle, rigidity, myoclonic jerks
  Target                                                       Dendrotoxin-binding CNS VGKC (Kv1.1, 1.2, 1.6)                                                NMDAR, probably principally NR1                                                                                     GluR1/2 dimers, epitopes on GluR1 or GluR2                                 AQP4                                                                                                                       GlyR alpha 1a
  Tumour association or other pathology                        Thymoma                                                                                       Ovarian teratomas in young women                                                                                    Breast cancer, small-cell lung cancer, thymoma                             Very rare                                                                                                                  Not common
  Main pathogenic mechanism                                    Increased internalisation                                                                     Increased internalisation Complement-mediated mechanisms not explored                                               Increased internalisation Complement-mediated mechanisms not explored      Complement-mediated mechanisms important Increased internalisation of AQP4 and increased turnover of EAAT1 in astrocytes   No evidence to date
  Disease course                                               Self-limiting in most cases Immunotherapies hasten recovery and reduce long-term disability   Tumour cases do well after removal and treatments Nontumour cases may do less well and have a tendency to relapse   Responds to immunotherapies but has tendency to relapse                    Historically a severe relapsing remitting disease with bad prognosis May do better with intensive immunotherapies          First patient described returned to work after intense immunotherapies
  Intrathecal synthesis of specific antibody Normal \<1.5^a^   1.5 to 40, variable but sometimes high                                                        10 to 30, High                                                                                                      High                                                                       Little or none (\<1.5)                                                                                                     1.5 to \>50, variable but sometimes very high

^a^This is calculated as (cerebrospinal fluid \[CSF\] titre of specific antibody/concentration of CSF IgG) / (serum titre of specific antibody/concentration of serum IgG). Values above 1.5 are usually considered indicative of synthesis within the CSF compartment rather than the result of passive leakage. The values given are based on our unpublished experience and from data presented in \[[@bib-018],[@bib-021]\]. It needs to be appreciated that the normal serum IgG concentration is about 400 times higher than the normal CSF IgG concentration. Therefore, even in the presence of substantial intrathecal synthesis, the serum concentration of specific antibody will be higher than the CSF concentration. Ab, antibody; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; AQP4, aquaporin-4; CNS, central nervous system; EAAT1, excitatory amino acid transporter 2; GluR, glutamate receptor; GlyR, glycine receptor; NMDAR, *N*-methyl-[d]{.smallcaps}-aspartate receptor; VGKC, voltage-gated potassium channel.

Meanwhile, a completely different condition was found to be associated with antibodies to a water channel. Neuromyelitis optica (NMO, or Devic disease) has usually been considered to be part of the spectrum of inflammatory demyelinating disorders, of which multiple sclerosis is the best known. However, NMO is a distinct inflammatory condition of the optic nerves which involves severe visual failure and inflammation of the spinal cord causing longitudinally extensive transverse myelitis (at least three spinal cord segments with high signal on MRI), that leads to para- or tetraparesis, sensory deficits and bladder disturbances. Patients show variable recovery with immunomodulatory treatments but accumulate disability over time, and mortality is high if the disease is not appropriately treated \[[@bib-022]\]. In 2004, antibodies binding around small vessels, under the pia and in Virchow-Robin spaces were defined by immunofluoresence \[[@bib-023]\], and the target was subsequently identified as aquaporin-4 (AQP4), the only water channel expressed strongly in the brain (and also in kidney and stomach) \[[@bib-024]\]. Antibodies to AQP4 bind to the astrocyte endfeet that abut CNS blood vessels and are thought to be important contributors to the integrity of the blood-brain barrier. The antibodies lead to substantial loss of surface AQP4 by internalisation and activate complement with formation of the membrane attack complex, leading to cellular damage \[[@bib-025]\]. They also reduce astrocyte expression of excitatory amino acid transporter 2 (EAAT2) with reduced reuptake of glutamate \[[@bib-026]\] and hence potential excitotoxic damage. Interestingly, it seems that AQP4 and EAAT2 are part of a macromolecular complex \[[@bib-025]\]. Whether these changes alone lead to the substantial inflammatory infiltrates, areas of demyelination, loss of AQP4 and sometimes necrosis that are found in lesions \[[@bib-027],[@bib-028]\] is not yet clear, but increases in antibody levels are associated with clinical relapses, and AQP4 antibodies decrease in parallel with clinical improvement after immunosuppression \[[@bib-029]\]; overall, there seems little doubt that the antibodies contribute to the pathology \[[@bib-022]\].

Finally, another receptor target is emerging in patients with rare spinal and brain stem syndromes. In one adult male who presented with excessive startle and progressive encephalomyelitis with rigidity and myoclonus (PERM), a form of stiff person syndrome, antibodies to glycine receptor alpha 1 pentamers (GlyR1s) were identified \[[@bib-030]\]. The GlyR1 antibodies disappeared with treatment and the patient made a substantial clinical recovery. These antibodies are now being found in other patients with related disorders (A Vincent, I Leite, H-M Meinck, unpublished data).

Future directions {#s03}
=================

There are some important lessons that arise out of these exciting advances. Once defined, the antibodies are best identified by binding to native proteins extracted from mammalian tissue in mild detergents (VGKCs), or better still to the native protein expressed in an appropriate human cell line (NMDARs, AMPARs, AQP4, GlyR), rather than to short peptides that do not represent the native conformation of the target antigen. The protein must be expressed on the cell surface and the cells should be unpermeabilised so that only cell surface-binding antibodies are detected (this ensures that they are potentially pathogenic, in contrast to those antibodies to intracellular components found in paraneoplastic disorders). Clustering of the antigen by use of intracellular scaffolding proteins can increase sensitivity and specificity as recently demonstrated for AChR antibodies \[[@bib-031]\]. In addition, the antibodies should be shown to bind to the extracellular surface of neurons or astrocytes cultured from mammalian tissues and to induce relevant biological changes in such cultures. In the future, one hopes that these studies will extend to examining the effects of these recently discovered antibodies on neuronal activity in brain slices *in vitro* and in animal models *in vivo*.

Considering the diversity of ion channels and receptors in the nervous system, it would be strange if there were no other autoimmune channelopathies to be discovered, diagnosed and treated. Until now, most of the target channels have been identified by a candidate approach, but if the target for binding to the cultured cells is sufficiently abundant, as appears to be the case for AMPARs \[[@bib-021]\], it is possible to immunoprecipitate the target using the relatively pure CSF IgG from the patients \[[@bib-021]\]; this technique has potential for identifying new targets in the future. Even the total patient plasma IgG can be used to identify antigens by this approach when a suitable cell preparation or cell line is identified \[[@bib-032]\].

In each of these diseases, CSF antibodies are found, and there is often evidence of high concentrations of CSF-specific antibody relative to CSF IgG concentration when compared with similar measurements in serum ('intrathecal synthesis', [Table 2](#tbl-002){ref-type="table"}), but the absolute concentration of antibody is still higher in serum than in CSF. A major question, therefore, is whether the antibodies that are pathogenic come directly from the blood into the CNS parenchyma via a 'leaky' or damaged blood-brain barrier or whether the disorders require the presence of specific antibodies in the CSF. The latter could be the result of passive diffusion across the choroid plexus and/or intrathecal synthesis by B cells that have gained entry to the CNS and synthesise the antibodies in the intrathecal compartment. These considerations are not purely academic. Does intrathecal synthesis decrease with current systemic treatments and increase if the patient relapses? Do immune responses ever begin in the CNS and remain undetectable in the serum? And importantly, should drugs and therapies be specifically targeted to the CSF compartment rather than to the systemic immune system? These are just some of the questions that arise from the identification of these new autoimmune disorders, and the answers will likely come from both focused human studies and animal models.
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